Praxis Precision Medicines Inc (NASDAQ: PRAX) kicked off on Friday, down -6.66% from the previous trading day, before settling in for the closing price of $76.88. Over the past 52 weeks, PRAX has traded in a range of $13.50-$86.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 46.64%. With a float of $17.23 million, this company’s outstanding shares have now reached $18.64 million.
In an organization with 82 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 79.44%, operating margin of -10219.0%, and the pretax margin is -9409.22%.
Praxis Precision Medicines Inc (PRAX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Praxis Precision Medicines Inc is 7.63%, while institutional ownership is 95.22%. The most recent insider transaction that took place on Nov 14 ’24, was worth 660,827. In this transaction General Counsel and Secretary of this company sold 8,239 shares at a rate of $80.20, taking the stock ownership to the 10,301 shares. Before that another transaction happened on Nov 14 ’24, when Company’s Principal Accounting Officer sold 5,188 for $81.78, making the entire transaction worth $424,318. This insider now owns 5,613 shares in total.
Praxis Precision Medicines Inc (PRAX) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -2.97 earnings per share (EPS), higher than consensus estimate (set at -3.17) by 0.2. Wall Street market experts anticipate that the next fiscal year will bring earnings of -2.99 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 46.64% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -14.60% during the next five years compared to -10.28% drop over the previous five years of trading.
Praxis Precision Medicines Inc (NASDAQ: PRAX) Trading Performance Indicators
Take a look at Praxis Precision Medicines Inc’s (PRAX) current performance indicators. Last quarter, stock had a quick ratio of 10.96. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 780.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -10.30, a number that is poised to hit -2.79 in the next quarter and is forecasted to reach -11.14 in one year’s time.
Technical Analysis of Praxis Precision Medicines Inc (PRAX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.41 million. That was better than the volume of 0.28 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 63.90%. Additionally, its Average True Range was 5.43.
During the past 100 days, Praxis Precision Medicines Inc’s (PRAX) raw stochastic average was set at 68.70%, which indicates a significant increase from 46.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.20% in the past 14 days, which was higher than the 59.34% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $67.00, while its 200-day Moving Average is $53.86. However, in the short run, Praxis Precision Medicines Inc’s stock first resistance to watch stands at $75.99. Second resistance stands at $80.23. The third major resistance level sits at $83.45. If the price goes on to break the first support level at $68.53, it is likely to go to the next support level at $65.31. Assuming the price breaks the second support level, the third support level stands at $61.07.
Praxis Precision Medicines Inc (NASDAQ: PRAX) Key Stats
The company with the Market Capitalisation of 1.25 billion has total of 18,638K Shares Outstanding. Its annual sales at the moment are 2,450 K in contrast with the sum of -123,280 K annual income. Company’s last quarter sales were recorded 300 K and last quarter income was -51,910 K.
